Home/Filings/4/0001827564-22-000002
4//SEC Filing

Holdbrook Mark J. 4

Accession 0001827564-22-000002

CIK 0001819790other

Filed

Mar 10, 7:00 PM ET

Accepted

Mar 11, 4:13 PM ET

Size

7.7 KB

Accession

0001827564-22-000002

Insider Transaction Report

Form 4
Period: 2022-03-09
Holdbrook Mark J.
V.P., Clinical Affairs
Transactions
  • Award

    Stock Option (right to buy)

    2022-03-09+36,17336,173 total
    Exercise: $19.59Exp: 2032-03-08Common Stock (36,173 underlying)
  • Award

    Restricted Stock Units

    2022-03-09+10,61210,612 total
    Common Stock (10,612 underlying)
Footnotes (3)
  • [F1]25% of the option shares shall vest on March 9, 2023, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service.
  • [F2]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
  • [F3]25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

Issuer

Tarsus Pharmaceuticals, Inc.

CIK 0001819790

Entity typeother

Related Parties

1
  • filerCIK 0001827564

Filing Metadata

Form type
4
Filed
Mar 10, 7:00 PM ET
Accepted
Mar 11, 4:13 PM ET
Size
7.7 KB